Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MET Exon 14 Alterations and New Resistance Mutations to Tyrosine Kinase Inhibitors: Risk of Inadequate Detection with Current Amplicon-Based NGS Panels.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Oct 2017

Poirot Brigitte, Doucet Ludovic, Benhenda Shirine, Champ Jérôme, Meignin Véronique, Lehmann-Che Jacqueline

Abstract excerpt

INTRODUCTION: Targeted therapies such as tyrosine kinase inhibitors (TKIs) have dramatically improved the treatment of lung adenocarcinoma, and detection of activating mutations of genes such as EGFR or anaplastic lymphoma kinase gene (ALK) is now mandatory in the clinical setting. However, additional targetable alterations are continuously being described and forcing us to adapt our detection methods. Here we...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to MET gene

Share to ROS1 gene

Share to High-Throughput Nucleotide Sequencing

Share to Mutation

Share to Protein Kinase Inhibitors

Source

Identifiers

PMID: 28779874
DOI: 10.1016/j.jtho.2017.07.026

Genes

ALK
EGFR
MET
ROS1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MET Exon 14 Alterations and New Resistance Mutations to Tyrosine Kinase Inhibitors: Risk of Inadequate Detection with Current Amplicon-Based NGS Panels.PMID 28779874Read ↗

Highly accurate DNA-based detection and treatment results of MET exon 14 skipping mutations in lung cancer.Semantic proximity Read ↗

Detection of MET exon 14 skipping mutations in non-small cell lung cancer: overview and community perspective.Semantic proximity Read ↗

Characterization of Non-Small-Cell Lung Cancers With MET Exon 14 Skipping Alterations Detected in Tissue or Liquid: Clinicogenomics and Real-World Treatment Patterns.Semantic proximity Read ↗

Real-world analysis of MET exon 14 mutations in non-small cell lung cancer: a retrospective study from two Swedish hospitals.Semantic proximity Read ↗

Detection of MET Exon 14 Skipping Alterations in Lung Cancer Clinical Samples Using a PCR-Based Approach.Semantic proximity Read ↗

Refining patient selection of MET-activated non-small cell lung cancer through biomarker precision.Semantic proximity Read ↗

An Alert to Possible False Positives With a Commercial Assay for MET Exon 14 Skipping.Semantic proximity Read ↗

MET exon 14 skipping mutations in non-small-cell lung cancer a 3 years screening experienceSemantic proximity Read ↗

Optimization of Routine Testing for MET Exon 14 Splice Site Mutations in NSCLC Patients.Semantic proximity Read ↗

Brief Report: Critical Role for DNA-Based Sequencing in Discriminating Distinct Primary Lung Cancers With Different MET Exon 14 Skipping Mutations.Semantic proximity Read ↗

Novel MET exon 14 skipping analogs characterized in non-small cell lung cancer patients: A case study.Semantic proximity Read ↗

MET Exon 14–altered Lung Cancers and MET Inhibitor ResistanceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.